EP0802914B1 - Aryl- and heteroaryl- purine and pyridopyrimidine derivatives - Google Patents
Aryl- and heteroaryl- purine and pyridopyrimidine derivatives Download PDFInfo
- Publication number
- EP0802914B1 EP0802914B1 EP96934673A EP96934673A EP0802914B1 EP 0802914 B1 EP0802914 B1 EP 0802914B1 EP 96934673 A EP96934673 A EP 96934673A EP 96934673 A EP96934673 A EP 96934673A EP 0802914 B1 EP0802914 B1 EP 0802914B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- pyrimidine
- pyrido
- methoxy
- oxindol
- purine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 CC(*)(C=C1)C=Nc2c1c(O)ncn2 Chemical compound CC(*)(C=C1)C=Nc2c1c(O)ncn2 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
- C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/36—Sulfur atom
- C07D473/38—Sulfur atom attached in position 6
Definitions
- the present invention relates to new bicyclic condensed pyrimidine compounds, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents, in particular as tyrosine kinase inhibitors.
- EP-A-0414386 discloses 4-substituted pyrido[2,3-d]pyrimidine compounds which are plant fungicides, miticides and insecticides.
- WO 90/09178 discloses 6,9-disubstituted purine compounds useful in adenosine-mediated lipolysis, cardiovascular diseases and bronchodilatation.
- EP-181129 discloses N6-substituted deoxyribose analogs of adenosines, having analgesic, neuroleptic and antihypertensive activity, and intermediates for their preparation.
- the present invention provides novel bicyclic condensed pyrimidine compounds having the following general formula (I) wherein
- the X bridge may be located on either of the ring B moieties, preferably it is located on the benzene ring.
- the R 3 substituent is only located on the imidazole ring on a N-ring atom.
- the R 4 substituent is only located on the pyridine ring, preferably it is attached at the ⁇ -position.
- the R 1 and R 2 substituents in tetralin and indane may be on either of the ring moieties, preferably they are attached to the benzene moiety. In 2-oxindole the R 1 and R 2 substituents are preferably located on the benzene moiety.
- R 1 and R 2 substituents are preferably attached to the benzene moiety when B is tetralin, indane or 2-oxindole.
- the X bridge is preferably linked to position 1 or 2 when B is tetralin and to position 5 when B is indane or 2-oxindole.
- An alkyl group or an alkyl moiety in a alkoxy group may be branched or straight alkyl chains.
- a C 1 -C 4 alkyl group is preferably a C 1 -C 2 alkyl, that is ethyl or methyl.
- a C 1 -C 4 alkoxy group is preferably a methoxy or ethoxy group.
- a halogen atom is for example fluoro, chloro, bromo or iodio, in particular bromo or fluoro. It is understood that when A is a 4,5-fused imidazole moiety then a purine ring is formed and when A is a 2,3-fused pyridine moiety then a pyrido[2,3-d]pyrimidine ring is formed.
- tetralin is meant to refer to 5,6,7,8-tetrahydronaphthalene.
- salts of the compounds of the invention include acid addition salts with inorganic acids, e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acid or organic acids, e.g. acetic, trifluoracetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acid.
- inorganic acids e.g. nitric, hydrochloric, hydrobromic, sulphuric, perchloric and phosphoric acid or organic acids, e.g. acetic, trifluoracetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic and salicylic acid.
- Preferred compounds of the invention are the compounds of formula (I), wherein X, A and B are as defined above; R 1 is hydrogen or halogen, R 4 is hydrogen or C 1 -C 4 alkoxy, and R 2 and R 3 are H; and the pharmaceutically acceptable salts thereof.
- Examples of preferred specific compounds of formula (I) are the following compounds:
- An object of the present invention is also to provide a bicyclic condensed pyrimidine compound of formula (I) as defined above, or a pharmaceutically acceptable salt thereof, for use as an active therapeutic substance, in particular as tyrosine kinase inhibitor.
- a further object of the invention are pharmaceutical compositions comprising a compound of formula (I), as defined above, or a pharmaceutically salt thereof, as an active principle, and a pharmaceutically acceptable excipient (which can be a carrier and/or diluent).
- a further object of the present invention is a bicyclic condensed pyrimidine compound of formula (IA) wherein
- Examples of preferred specific compounds of formula (IA) are the following compounds:
- a further object of the invention are pharmaceutical compositions comprising a compound of formula (IA), as defined above, as an active principle and a pharmaceutically acceptable excipient (which can be a carrier and/or diluent).
- a pharmaceutically acceptable excipient which can be a carrier and/or diluent.
- An object of the present invention is also to provide the use of a bicyclic condensed pyrimidine compound of formula (IB) wherein
- Examples of preferred specific compounds of formula (IB) are the following compounds:
- Object of the present invention is also to provide a pharmaceutical composition having tyrosine kinase inhibiting activity comprising a pharmaceutically acceptable carrier and/or diluent, and as an active principle a compound of formula (IB) or a pharmaceutically acceptable salt thereof.
- a pharmaceutical composition having tyrosine kinase inhibiting activity comprising a pharmaceutically acceptable carrier and/or diluent, and as an active principle a compound of formula (IB) or a pharmaceutically acceptable salt thereof.
- the compounds of formula (I), (IA), (IB), and the pharmaceutically acceptable salts thereof are altogether defined hereafter as the "compounds of the invention” or as the "active agents" of the invention.
- the compounds of the invention can be obtained by an analogy process.
- the compounds of formula (I), and the salts thereof can be obtained by a process comprising:
- a leaving group L in a compound of formula (II) is for instance chloro, 1,2,4-triazol-1-yl or methylthio.
- reaction of a compound of formula (II) with a compound of formula (III) according to process step a) may be carried out using known methods, e.g. as described by Bullock et al. in J.Am.Chem.Soc. 78 , 3693 (1956).
- the reaction is carried out in the presence of a suitable organic inert solvent, for example an alkanol or ester such as methanol, ethanol, isopropanol, methyl cellosolve or ethyl acetate, a halogenated solvent such as dichloromethane or chloroform, an ether such as tetrahydrofuran or dioxane, a dipolar aprotic solvent such as dimethylformamide or dimethylacetamide.
- a suitable organic inert solvent for example an alkanol or ester such as methanol, ethanol, isopropanol, methyl cellosolve or ethyl acetate, a halogenated solvent such as
- the solvents isopropanol or methyl cellosolve are used.
- the reaction is conveniently carried out at a temperature in the range from about 10 to about 150°C, preferably in the range from about 20 to about 80°C.
- 1 equivalent of amine compound (III) is used, thus giving the hydrochloride salt, which precipitates on cooling.
- the salt may be treated with a suitable base in the presence of an appropriate solvent such as the ones mentioned above.
- Suitable bases are e.g. organic amines such as triethylamine or pyridine, or inorganic bases such as sodium carbonate or sodium hydroxide.
- organic amines such as triethylamine or pyridine
- inorganic bases such as sodium carbonate or sodium hydroxide.
- reaction of a compound of formula (II) with a compound of formula (IV) according to process step b) may be carried out by using known methods, e.g. as described by Prasad et al. in J.Am.Chem.Soc. 79 , 6401 (1957).
- the reaction is preferably carried out in a protic solvent, e.g. water or aqueous alkanol such as aqueous methanol, ethanol or isopropanol in the presence of a suitable alkali base such as sodium or potassium hydroxide.
- the reaction temperatures are ranging from about 0 to about 100°C, preferably the range is from about 50 to about 100°C.
- the hydroxy compound of formula (IV) is at first transformed into its metal salt in an aprotic solvent, which is then reacted with the compound of formula (II).
- the metallation of compound (IV) may be carried out with metal compounds like NaH or NaNH 2 in an aprotic solvent such as tetrahydrofuran, ethyl ether, DMF or benzene.
- the metal salt is then reacted with compound (II) in the same aprotic solvent at temperatures ranging from about 0 to about 100°C, preferably in the range from about 20 to about 40°C.
- reaction of a compound of formula (II) with a thiol compound of formula (V) according to process step c) may be carried out using known methods, e.g. as reviewed in Heterocyclic Compounds vol.8, page 335 (1967, Editor R.C. Elderfield).
- Suitable reaction solvents are protic solvents, e.g. water, alkanols such as methanol, ethanol and isopropanol or ethers such as tetrahydrofuran or dioxane.
- a suitable alkali base e.g.
- reaction temperature may vary from about 0 to about 120°C, preferably from about 40 to about 80°C.
- the cyclization of the ortho diamino compound of formula (VI) according to process step d) may be carried out by known methods, e.g. as reviewed in Rodd's Chemistry of Carbon Compounds vol.IV, part L, page 5 (1980, Elsevier Scientific Publishing Company).
- an important modification of the Traube cyclization method can be applied which uses formamide instead of formic acid, e.g. as described by Daly et al. in J.Org.Chem. 21 , 177 (1956).
- the compound (VI) is cyclized in formamide solution at temperatures ranging from about 100 to about 210°C, preferably at reflux temperature.
- the hydrolysis and decarboxylation of a compound of formula (VII) according to process step e) may be carried out using known methods, e.g. as described in J.Het.Chem. 14, 1081 (1977) by A.Scoville and F.X.Smith.
- Suitable reaction solvents are protic solvents, e.g. water or aqueous alkanols such as methanol, ethanol or isopropanol.
- the hydrolysis step is carried out in alkaline conditions, e.g. in the presence of an alkali hydroxide such as sodium or potassium hydroxide.
- the reaction temperature may range from room to reflux temperature, preferably reflux temperature is applied.
- the decarboxylation step is carried out in slightly acidic conditions, e.g. in the presence of a mineral acid such as hydrochloric acid.
- the reaction temperature may vary from room to reflux temperature, preferably reflux temperature is used.
- a C 1 -C 4 alkyl or benzyl halide is reacted with the N 9 -unsubstituted purine in an appropriate organic solvent, preferably in a dipolar aprotic solvent such as DMF, DMAA or DMSO, and in the presence of an inorganic base such as sodium hydroxide or potassium carbonate.
- an appropriate organic solvent preferably in a dipolar aprotic solvent such as DMF, DMAA or DMSO
- an inorganic base such as sodium hydroxide or potassium carbonate.
- the compounds of formula (II), wherein A is a 4,5-fused imidazole ring and L is chloro, are known or may be obtained from a compound of formula (VIII) by known N-alkylation methods, e.g. as reviewed in Heterocyclic Compounds vol.8, page 372 (1967, Editor R.C.Elderfield) and as mentioned above.
- the compound of formula (VIII) is commercially available.
- the compounds of formula (II), wherein A is a 2,3-fused pyridine ring are known or may be obtained by known methods from known compounds.
- the 4-chloro compounds of formula (II), wherein A is a 2,3-fused pyridine ring and L is chloro are prepared by chlorodehydroxylation of the corresponding 4-hydroxy-pyrido[2,3-d]pyrimidine derivatives of formula (IX) using conventional methods, e.g. by reaction with POCl 3 .
- the intermediate of formula (II), wherein A is a 2,3-fused pyridine ring and L is 1,2,4-triazol-1-yl can be prepared e.g.
- the compounds of formula (VII) can be made by using the process of A.Scoville and F.X.Smith as described in J.Het.Chem. 14 , 1081 (1977). Accordingly a compound of formula (II), in which L is chloro, A is a 2,3-fused pyridine ring and R 4 is as defined above, is reacted with a compound of formula (X) in which B, R 1 and R 2 are as defined above.
- the compounds of formulae (III), (IV), (V), (VI), and (X) are either known compounds or may be obtained by known methods from known compounds.
- groups present which need to be protected before the above-described reactions are performed, they may be protected before the reaction takes place and then deprotected at the end of the reaction, according to well known methods in organic chemistry.
- the new compounds of formula (IA) can be analogously obtained.
- the compounds of the invention possess specific tyrosine kinase inhibiting activity. It is believed that tyrosine kinase inhibitors may be of great importance in the control of uncontrolled cellular reproduction, i.e. in cellular reproduction disorders. Hence, the compounds according to the present invention can be useful in the treatment of pathological proliferation disorders in mammals, including humans. Typical examples of such disorders are tumors, including leukemia, and psoriasis. The compounds of the invention can also be useful in inhibiting the development of the atheromatous plaque and in the control of angiogenesis and as anti-metastatic agents.
- RNA tumor viruses possess such an oncogene sequence whose expression determines neoplastic conversion of infected cells.
- oncogene-encoded proteins such as pp60 v-src , p70 gag-yes , p130 gag-fps and p70 gag-fgr display protein tyrosine kinase activity, that is they catalyze the transfer of the g-phosphate from adenosine triphosphate (ATP) to tyrosine residues in protein substrate.
- ATP adenosine triphosphate
- tyrosine kinase receptors In normal cells, several growth factor receptors, for example the receptors for PDGF, EGF, ⁇ -TGF and insulin, display tyrosine kinase activity. Binding of the growth factor (GF) activates the receptor tyrosine kinase to undergo autophosphorylation and to phosphorylate closely adjacent molecules on tyrosine. Therefore, it is thought that the phosphorylation of these tyrosine kinase receptors plays an important role in signal transduction and the principal function of tyrosine kinase activity in normal cells is to regulate cell growth.
- GF growth factor
- tyrosine kinases that are either overproduced and/or display altered substrate specificity may cause loss of growth control and/or neoplastic transformation.
- a specific inhibitor of tyrosine kinase can be useful in investigating the mechanism of cancerogenesis, cell proliferation and differentiation and it can be effective in the prevention and chemotherapy of cancer and in other pathological proliferative conditions.
- the compounds according to the present invention can be useful in the treatment of pathological proliferation disorders in mammals, including humans.
- a human or animal e.g. a mammal, can thus be treated by a method comprising the administration thereto of a therapeutically effective amount of one of the compounds of the invention. In this way the condition of the human or animal may be improved.
- Amelioration of the disease state or disorder from which the human or animal is suffering can be achieved.
- Typical examples of such disorders are benign and malignant tumours, including leukemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumour, malignant neoplasm of the bladder, breast, lung or thyroid, neoplasias of epithelial origin, such as mammacarcinoma.
- leukemia such as myeloblastic leukaemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumour, malignant neoplasm of the bladder, breast, lung or thyroid, neoplasias of epithelial origin, such as mammacarcinoma.
- they can be useful in the treatment of epidermal hyperproliferation, such as psoriasis.
- the compounds of the invention can also be useful in inhibiting the development of the atheromatous plaque and restenosis, in the control of angiogenesis, as anti-metastatic agents and in treating diabetic complications. They have also utility in the control of immune system diseases, e.g. as immunosuppressants, as far as protein tyrosine kinases, particularly Zap70, p56 lck and p59 fyn, are strongly involved in the control of the proliferation of the immune system. Moreover, the compounds of the invention have utility in the treatment of Alzheimer's disease due to the pivotal role played by tyrosine phosphorylation (e.g. Tau proteins) in the development of the disease. The tyrosine specific protein kinase activity of the compounds of the invention is shown, e.g., by the fact that they are active in the in vitro and in vivo test described herebelow.
- tyrosine phosphorylation e.g. Tau proteins
- the EGFR autophosphorylation was assayed using A431 crude membrane extracts as source of the receptor.
- Membranes were prepared as reported by A. Levitzky et al. (Methods in Enzymology 201, 347 (1991) with minor modifications and adapting the method to the A431 human epidermoid carcinoma cell line. Briefly, low density cells growing in RPMI 1640 plus 10% foetal calf serum were detached using 1 mM EDTA in phosphate buffer saline (PBS) and lysed in cold Lysing buffer (1 ml/10 6 cells) (20 mM HEPES pH 7.6, 10 mM NaCl, 2 mM EDTA, 10 ⁇ g/ml Aprotinin, 10 ⁇ g/ml Luepeptin, 1 mM PMSF).
- PBS phosphate buffer saline
- Cells were homogenized by 10 strokes in Dounce homogenizer. Nuclei and debris were removed by low speed centrifugation. Membranes were pelletized by ultracentrifugation (1 h, 100000 x g) and resuspended in cold HNG buffer (50 mM HEPES pH 7.6, 125 mM NaCl, 10% glycerol). Protein concentration, determined by Pierce BCA method, was adjusted to 1.5-2 mg/ml. Aliquots were stored at -80°C.
- A431 membranes 2.5 mg of protein/sample pre-treated with EGF (final concentration 200 nM) for 30 min at 4°C were incubated in 30 ⁇ l of reaction buffer (50 mM HEPES pH 7.6, 125 mM NaCl, 12 mM Mg-acetate, 2 mM MnCl 2 , 1 mM NaVO 3 , 1 mM ATP, 1 mCi ⁇ - 32 P-ATP) for 1 min at 0°C in the presence of increasing concentrations of compounds.
- the reaction was stopped with Laemly solution.
- the samples were heated 5 min at 95°C and submitted to SDS-PAGE (7.5% acrylamide gel).
- VAP assay Inhibition of cellular tyrosine autophosphorylation
- EGF is able to induce the phosphorylation in tyrosine of a specific set of intracellular proteins including EGFR itself.
- This increase in tyrosine phosphorylation was measured using the Vectastain-ABC-AP kit (Vector Laboratories) following the manufacturer's instructions. Briefly, 2 x 10 4 A431 cells per well were plated into a microtiter plate and incubated for 3 days at 37°C/ 5% CO 2 until the cultures reached confluency. Cell monolayers were washed with PBS and covered with fresh medium containing 0.1% bovine serum albumin (BSA).
- BSA bovine serum albumin
- test compounds Serial dilution of test compounds were added 2 h before the addition of 100 ng/ml EGF; after 10 min stimulation the culture medium was withdrawn, cells were washed 2 times with PBS and fixed for 10 min with cold methanol (-20°C). After fixation 200 ml of blocking solution (3% BSA in PBS, 0.2% Tween 20, 1% normal horse serum) were added for 1 h at 37°C. Blocking solution was replaced with 3% BSA in PBS containing the anti-phosphotyrosine antibody 4G10 (UBI) diluted 1:30000 and incubated for 1 h. Bound antibodies were revealed using the Vectastain-ABC-AP kit with p-nitrophenyl phosphate as the substrate. Reaction was developed for 30 min in the dark and the plates were read at 405 nm.
- the antiproliferative activity of the test compounds was assayed on A431 cells using the SRB colorimetric method (P. Skehan et al.: J.Natl.Cancer Inst. 1990, 82 , 1107-1112).
- A431 cells were seeded into 96-well microtiter plates (5000 cells/cm 2 ) and incubated overnight at 37°C/5% CO 2 .
- Compounds dissolved in DMSO were added in serial dilution and plates were incubated for 3 days at 37°C/5% CO 2 .
- Cells were fixed with cold TCA (10% final concentration) and stained with 0.4% Sulforhodamine B dye in 1% acetic acid for 30 min.
- Dye was solubilized with 10 mM Tris (pH 10.4) and microtiters were read at 550 nm.
- the compounds of the invention can be used safely in medicine.
- the compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the forms of tablets, capsules, sugar- and film-coated tablets, liquid solutions or suspensions; rectally, in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous injection or infusion; or topically.
- the dosage depends on the age, weight, condition of the patient and administration route.
- the dosage adopted for oral administration to adult humans for the compounds 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine and N 6 -(1-tetralyl)-adenine may range from about 5 to about 150-200 mg per dose, from 1 to 5 times daily. Of course, these dosage regimes may be adjusted to provide the optimal therapeutic response.
- the pharmaceutical compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
- the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g.
- binding agents e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone
- disaggregating agents e.g. a starch, alginic acid, alginates or sodium starch glycolate, effervescing mixtures
- dyestuffs efferv
- Said pharmaceutical preparations may be manufactured in known manner, by means of mixing, granulating, tabletting, sugar-coating or film-coating processes.
- the liquid dispersion for oral administration may be, e.g., syrups, emulsions and suspensions.
- the syrup may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
- the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
- the suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g.
- compositions for topical application e.g. creams, lotions or pastes, can be prepared by admixing the active ingredient with a conventional oleaginous or emulsifying excipient.
- the present invention also provides products containing a compound of the invention, that is a compound of formula (IB) or a pharmaceutically acceptable salt thereof, and an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- a compound of the invention that is a compound of formula (IB) or a pharmaceutically acceptable salt thereof
- an additional antitumor agent as a combined preparation for simultaneous, separate or sequential use in anticancer therapy.
- anticancer therapy is meant to comprise both a single antitumour drug and "cocktails", i.e. a mixture of such drugs, according to the clinical practice.
- antitumour agents examples include doxorubicin, daunomycin, epirubicin, idarubicin, etoposide, fluorouracil, melphalan, cyclophosphamide, bleomycin, vinblastin and mitomycin or a mixture of two or more thereof.
- the compounds of the invention can therefore be used in a treatment to ameliorate a cancer.
- an antitumour agent for example an anthracycline glycoside such as doxorubicin, daunomycin, epirubicin or idarubicin as mentioned above, together with the antitumour agent.
- an antitumour agent such as an anthracycline glycoside can be administered to improve the condition of a patient having leukemia such as myeloblastic leukemia, lymphoma, sarcoma, neuroblastoma, Wilm's tumour or malignant neoplasm of the bladder, breast, lung or thyroid.
- a slurry of 4-chloro-pyrido[2,3-d]pyrimidine (1.656 g, 10 mM) and 5-(5-indanyl) barbituric acid (2.443 g, 10 mM) is stirred in an oil bath.
- the temperature is raised to 130°C in a period of 15 min.
- the temperature is further increased from 130°C to 170°C.
- the resulting solid is maintained for further 10 min at about 170°C.
- the reaction mixture is cooled, triturated with sodium bicarbonate solution and hexane.
- the solid is filtered off, washed with water and dried under vacuum.
- the raw product is submitted to the next step without further purification.
- 2-aminonicotinic acid 1.381 g, 10 mM
- formamide 2.70 g, 60 mM
- the reaction mixture is cooled and the resulting solid recrystallized from water to give about 1.030 g of title compound (70 % yield). mp 255-8°C.
- Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows: Composition (for 10,000 tablets): N 6 -(1-tetralyl) adenine 250 g Lactose 800 g Corn starch 415 g Talc powder 30 g Magnesium stearate 5 g
- N 6 -(1-tetralyl) adenine, the lactose and half of the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size.
- Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
- Capsules each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.
- Composition for 500 capsules N 6 -(5-indanyl) adenine 10 g Lactose 80 g Corn starch 5 g Magnesium stearate 5 g
- This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.
- Tablets each weighing 0.150 g and containing 25 mg of the active substance, can be manufactured as follows: Composition (for 10,000 tablets): 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine 250 g Lactose 800 g Corn starch 415 g Talc powder 30 g Magnesium stearate 5 g
- the 4-(5-indanylamino)-pyrido[2,3-d]pyrimidine, the lactose and half of the corn starch are mixed; the mixture is then forced through a sieve of 0.5 mm mesh size.
- Corn starch (10 g) is suspended in warm water (90 ml) and the resulting paste is used to granulate the powder. The granulate is dried, comminuted on a sieve of 1.4 mm mesh size, then the remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
- Capsules each dosed at 0.200 g and containing 20 mg of the active substance can be prepared.
- Composition for 500 capsules 4-(1-tetralylamino)-pyrido[2,3-d]pyrimidine 10 g Lactose 80 g Corn starch 5 g Magnesium stearate 5 g
- This formulation is encapsulated in two-piece hard gelatin capsules and dosed at 0.200 g for each capsule.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9523242.7A GB9523242D0 (en) | 1995-11-14 | 1995-11-14 | Aryl and heteroaryl purine compounds |
GB9523242 | 1995-11-14 | ||
GBGB9524131.1A GB9524131D0 (en) | 1995-11-24 | 1995-11-24 | Pyrido-pyrimidine compounds as tyrosine kinase inhibitors |
GB9524131 | 1995-11-24 | ||
PCT/EP1996/004460 WO1997018212A1 (en) | 1995-11-14 | 1996-10-14 | Aryl and heteroaryl purine compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0802914A1 EP0802914A1 (en) | 1997-10-29 |
EP0802914B1 true EP0802914B1 (en) | 2001-06-06 |
Family
ID=26308112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP96934673A Expired - Lifetime EP0802914B1 (en) | 1995-11-14 | 1996-10-14 | Aryl- and heteroaryl- purine and pyridopyrimidine derivatives |
Country Status (17)
Country | Link |
---|---|
US (1) | US5965563A (pt) |
EP (1) | EP0802914B1 (pt) |
JP (1) | JPH10512896A (pt) |
CN (1) | CN1168138A (pt) |
AR (1) | AR004320A1 (pt) |
AT (1) | ATE201873T1 (pt) |
AU (1) | AU7292096A (pt) |
BR (1) | BR9607089A (pt) |
CA (1) | CA2209598C (pt) |
DE (1) | DE69613211T2 (pt) |
EA (1) | EA000072B1 (pt) |
ES (1) | ES2159760T3 (pt) |
HU (1) | HUP9801177A3 (pt) |
IL (1) | IL121090A0 (pt) |
NO (1) | NO973198L (pt) |
PL (1) | PL321296A1 (pt) |
WO (1) | WO1997018212A1 (pt) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
TW321649B (pt) * | 1994-11-12 | 1997-12-01 | Zeneca Ltd | |
GB9424233D0 (en) * | 1994-11-30 | 1995-01-18 | Zeneca Ltd | Quinazoline derivatives |
GB9508535D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivative |
GB9508537D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
EP0824525B1 (en) * | 1995-04-27 | 2001-06-13 | AstraZeneca AB | Quinazoline derivatives |
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
ATE237596T1 (de) | 1996-02-13 | 2003-05-15 | Astrazeneca Ab | Chinazolinderivate und deren verwendung als vegf hemmer |
GB9603097D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline compounds |
ATE211134T1 (de) | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
US6344459B1 (en) | 1996-04-12 | 2002-02-05 | Warner-Lambert Company | Irreversible inhibitors of tyrosine kinases |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
ATE311884T1 (de) | 1997-07-12 | 2005-12-15 | Cancer Rec Tech Ltd | Cyclin-abhängige-kinase inhibierende purinderivate |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
IL139586A0 (en) | 1998-06-19 | 2002-02-10 | Pfizer Prod Inc | PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
US6933299B1 (en) | 1999-07-09 | 2005-08-23 | Smithkline Beecham Corporation | Anilinoquinazolines as protein tyrosine kinase inhibitors |
ES2295035T3 (es) | 1999-07-09 | 2008-04-16 | Glaxo Group Limited | Anilinoquinazolinas como inhibidores de proteina tirosina quinasa. |
EE05330B1 (et) | 1999-11-05 | 2010-08-16 | Astrazeneca Ab | Kinasoliini derivaadid kui VEGF-i inhibiitorid |
ES2208433T3 (es) | 1999-12-10 | 2004-06-16 | Pfizer Products Inc. | Compuestos de pirrolo(2,3-d)pirimidina como inhibidores de proteina quinasas. |
EA006153B1 (ru) | 2000-06-26 | 2005-10-27 | Пфайзер Продактс Инк. | СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИММУНОДЕПРЕССАНТОВ |
US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
WO2003053940A1 (en) * | 2001-12-20 | 2003-07-03 | Bristol-Myers Squibb Company | Barbituric acid derivatives as inhibitors of tnf-$g(a) converting enzyme (tace) and/or matrix metalloproteinases |
EP1352910A1 (en) * | 2002-04-10 | 2003-10-15 | Grünenthal GmbH | New analogs of nitrobenzylthioinosine |
AU2003276591A1 (en) | 2002-11-26 | 2004-06-18 | Pfizer Products Inc. | Method of treatment of transplant rejection |
SG145748A1 (en) * | 2003-08-15 | 2008-09-29 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
US7626030B2 (en) | 2004-01-23 | 2009-12-01 | Amgen Inc. | Compounds and methods of use |
CA2553423C (en) * | 2004-01-23 | 2012-03-20 | Amgen Inc. | Heterocyclic compounds for use in the treatment of cancer and the inhibition of angiogenesis |
PL1612210T3 (pl) * | 2004-06-29 | 2008-02-29 | Gruenenthal Gmbh | Nowe analogi nitrobenzylotioinozyny |
EP1827434B1 (en) * | 2004-11-30 | 2014-01-15 | Amgen Inc. | Quinolines and quinazoline analogs and their use as medicaments for treating cancer |
JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
KR20080080395A (ko) * | 2005-12-21 | 2008-09-03 | 아보트 러보러터리즈 | 항바이러스 화합물 |
WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
EP2094276A4 (en) * | 2006-12-20 | 2011-01-05 | Abbott Lab | ANTIVIRAL COMPOUNDS |
MX2010004620A (es) * | 2007-10-29 | 2010-07-28 | Amgen Inc | Derivados de benzomorfolina y metodos de uso. |
KR101335843B1 (ko) | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-d]피리미딘 화합물 |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
JP6235001B2 (ja) | 2012-05-21 | 2017-11-22 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ベンゾチエノピリミジン |
TW201412740A (zh) * | 2012-09-20 | 2014-04-01 | Bayer Pharma AG | 經取代之吡咯并嘧啶胺基苯并噻唑酮 |
ES2686909B1 (es) | 2017-03-22 | 2019-08-16 | Consejo Superior Investigacion | Compuestos inhibidores de cdc-7 y su uso para el tratamiento de patologias neurologicas |
FR3066761B1 (fr) * | 2017-05-23 | 2020-10-30 | Centre Nat Rech Scient | Nouveaux composes inhibiteurs des canaux ioniques |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0181129A2 (en) * | 1984-10-26 | 1986-05-14 | Warner-Lambert Company | N6-substituted deoxyribose analogs of adenosines |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB828522A (en) * | 1956-11-02 | 1960-02-17 | Geigy Ag J R | Purine derivatives and a process for the preparation thereof |
US3112192A (en) * | 1960-09-19 | 1963-11-26 | Shell Oil Co | Preservation of cut flowers |
US4751292A (en) * | 1985-07-02 | 1988-06-14 | The Plant Cell Research Institute, Inc. | Adamantyl purines |
DE3529497A1 (de) * | 1985-08-17 | 1987-02-26 | Boehringer Mannheim Gmbh | N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel |
AU626983B2 (en) * | 1989-01-31 | 1992-08-13 | Whitby Research, Inc. | N6-substituted 9-methyladenines |
US5034393A (en) * | 1989-07-27 | 1991-07-23 | Dowelanco | Fungicidal use of pyridopyrimidine, pteridine, pyrimidopyrimidine, pyrimidopyridazine, and pyrimido-1,2,4-triazine derivatives |
UA41297C2 (uk) * | 1991-11-25 | 2001-09-17 | Пфайзер, Інк. | Похідні індолу, фармацевтична композиція і спосіб лікування |
US5670501A (en) * | 1994-09-01 | 1997-09-23 | Discovery Therapeutics, Inc. | N-substituted 9-alkyladenines |
-
1996
- 1996-10-14 IL IL12109096A patent/IL121090A0/xx unknown
- 1996-10-14 US US08/860,717 patent/US5965563A/en not_active Expired - Fee Related
- 1996-10-14 EA EA199700107A patent/EA000072B1/ru not_active IP Right Cessation
- 1996-10-14 EP EP96934673A patent/EP0802914B1/en not_active Expired - Lifetime
- 1996-10-14 BR BR9607089A patent/BR9607089A/pt not_active Application Discontinuation
- 1996-10-14 CA CA002209598A patent/CA2209598C/en not_active Expired - Fee Related
- 1996-10-14 ES ES96934673T patent/ES2159760T3/es not_active Expired - Lifetime
- 1996-10-14 AT AT96934673T patent/ATE201873T1/de not_active IP Right Cessation
- 1996-10-14 JP JP9518527A patent/JPH10512896A/ja not_active Ceased
- 1996-10-14 HU HU9801177A patent/HUP9801177A3/hu unknown
- 1996-10-14 AU AU72920/96A patent/AU7292096A/en not_active Abandoned
- 1996-10-14 PL PL96321296A patent/PL321296A1/xx unknown
- 1996-10-14 CN CN96191448A patent/CN1168138A/zh active Pending
- 1996-10-14 WO PCT/EP1996/004460 patent/WO1997018212A1/en not_active Application Discontinuation
- 1996-10-14 DE DE69613211T patent/DE69613211T2/de not_active Expired - Fee Related
- 1996-11-13 AR ARP960105153A patent/AR004320A1/es unknown
-
1997
- 1997-07-09 NO NO973198A patent/NO973198L/no unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0181129A2 (en) * | 1984-10-26 | 1986-05-14 | Warner-Lambert Company | N6-substituted deoxyribose analogs of adenosines |
Also Published As
Publication number | Publication date |
---|---|
CA2209598C (en) | 2005-06-07 |
DE69613211D1 (de) | 2001-07-12 |
HUP9801177A3 (en) | 1998-11-30 |
DE69613211T2 (de) | 2001-11-15 |
ES2159760T3 (es) | 2001-10-16 |
EA000072B1 (ru) | 1998-06-25 |
NO973198D0 (no) | 1997-07-09 |
NO973198L (no) | 1997-07-09 |
CN1168138A (zh) | 1997-12-17 |
CA2209598A1 (en) | 1997-05-22 |
BR9607089A (pt) | 1997-11-11 |
JPH10512896A (ja) | 1998-12-08 |
HUP9801177A2 (hu) | 1998-09-28 |
MX9705010A (es) | 1997-10-31 |
EP0802914A1 (en) | 1997-10-29 |
EA199700107A1 (ru) | 1997-12-30 |
IL121090A0 (en) | 1997-11-20 |
WO1997018212A1 (en) | 1997-05-22 |
PL321296A1 (en) | 1997-12-08 |
US5965563A (en) | 1999-10-12 |
ATE201873T1 (de) | 2001-06-15 |
AR004320A1 (es) | 1998-11-04 |
AU7292096A (en) | 1997-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0802914B1 (en) | Aryl- and heteroaryl- purine and pyridopyrimidine derivatives | |
USRE49851E1 (en) | Pyridinylaminopyrimidine derivatives, preparation process and use thereof | |
EP0795556A1 (en) | 4-Substituted pyrrolopyrimidine compounds as tyrosin kinase inhibitors | |
US7169778B2 (en) | Pteridinones as kinase inhibitors | |
EP0964864B1 (en) | Pyrido 2,3-d pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation | |
US7232824B2 (en) | Quinazoline derivatives as medicaments | |
JP5417453B2 (ja) | タンパク質キナーゼ阻害剤 | |
US9834551B2 (en) | Substituted pyrrolo[2,3-b]pyrazines and substituted pyrazolo[3,4-b]pyridines as ITK and JAK kinase inhibitors | |
EP0853616B1 (en) | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors | |
US20220259235A1 (en) | EGFR Inhibitor, Composition, and Preparation Method Therefor | |
CZ164196A3 (en) | Pyrimidine derivatives with condensed heterocyclic ring and pharmaceutical compositions based thereon | |
WO1995028387A1 (fr) | Compose benzamide et utilisation medicale dudit compose | |
NZ516260A (en) | Fused imidazole compounds and remedies for diabetes mellitus | |
US20150152088A1 (en) | Alkynyl heteroaromatic compound and use thereof | |
US20220017520A1 (en) | Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine | |
WO2018086546A1 (zh) | 2-多取代芳环-嘧啶类衍生物及制备和医药用途 | |
MXPA97005010A (en) | Aril- and heteroaril-pur compounds | |
US20230295144A1 (en) | 2-polysubstituted aromatic ring-pyrimidine derivatives, preparation and medical application thereof | |
TWI750645B (zh) | 四氫哌喃基胺基-吡咯並嘧啶酮和使用彼之方法 | |
CN116655600A (zh) | 一种取代的2-芳氨基嘧啶类化合物、药物组合物及其用途 | |
MXPA98001408A (en) | Biciclic 4-aralchylaminopirimidine derivatives as tyrosin inhibitors cin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970710 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
17Q | First examination report despatched |
Effective date: 19990902 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RTI1 | Title (correction) |
Free format text: ARYL- AND HETEROARYL- PURINE AND PYRIDOPYRIMIDINE DERIVATIVES |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010606 Ref country code: LI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010606 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010606 Ref country code: CH Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010606 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010606 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010606 |
|
REF | Corresponds to: |
Ref document number: 201873 Country of ref document: AT Date of ref document: 20010615 Kind code of ref document: T |
|
REF | Corresponds to: |
Ref document number: 69613211 Country of ref document: DE Date of ref document: 20010712 |
|
ITF | It: translation for a ep patent filed |
Owner name: PHARMACIA & UPJOHN S.P.A. |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010906 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20010907 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20011015 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2159760 Country of ref document: ES Kind code of ref document: T3 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20051004 Year of fee payment: 10 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20061015 |
|
EUG | Se: european patent has lapsed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20070918 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20071019 Year of fee payment: 12 Ref country code: DE Payment date: 20071031 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20071017 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20071004 Year of fee payment: 12 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20081014 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20090630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081014 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081031 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081014 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20081015 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081015 |